Von Hippel-Lindau Disease Clinical Trial
Official title:
An International Collaborative Study: Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients
The purpose of the study is to investigate how best to screen for Endolymphatic sac tumors
(ELSTs) in von Hippel-Lindau (vHL) patients in order to diagnose the ELSTs while they are
still small so that hearing loss can be prevented.
Up to 16% of vHL patients are known to develop endolymphatic sac tumors in the inner ear
that can cause permanent hearing loss. However, the ELSTs are often not found before hearing
loss has already occurred. The challenge for doctors is to diagnose the ELSTs at early
stages before they cause often irreversible deafness. In order to find ELSTs before they
cause hearing loss, it is important to screen for the tumors prophylactically, that is
screen all vHL patients regardless of whether or not they have symptoms.
Who can join? Persons diagnosed with vHL who are at least 15 years old. The investigators
include patients WITH OR WITHOUT a diagnosed ELST.
What does it involve? You need to have a hearing test and an MRI of the brain, where the
inner ear can be seen, most vHL patients have already had this done as part of their
surveillance program.
Participants will be asked to participate in follow up examinations (hearing test and/or MRI
of the brain) after 2, 5, and 10 years.
How can I join? A doctor has to be responsible for the study in each country where vHL
patients participates.
Ask the doctor who manages your vHL examinations to contact us or contact us yourself and
the investigators will help you find a doctor in your country who will participate in the
study.
Background:
von Hippel-Lindau disease (vHL) is a hereditary multi-system disease requiring life-long
prophylactic surveillance. Affected individuals are predisposed to development of tumors and
cysts in multiple organs. In recent years, it has become apparent that endolymphatic sac
tumors (ELSTs), aggressive tumors of the petrous bone, occur in up to 16% of vHL patients.
ELST can lead to severe and progressive hearing loss and vertigo as well as other
audio-vestibular and neurological symptoms. However, surgical excision of tumors can
preserve patients' pre-operative hearing level, and eliminate most other audio-vestibular
symptoms. As even small ELSTs have been shown to lead to sudden and irreversible deafness,
timely diagnosis of ELSTs is essential to prevent severe audio-vestibular morbidity in ELST
patients. Several recommendations of ELST surveillance in vHL patients have been proposed;
some suggest that diagnostic tests for ELST should be done only in vHL patients with
subjective audio-vestibular symptoms, while others recommend audiological examinations or
MRI of the inner ear in all vHL patients as a screening tool. However, there has not
previously been much focus on specification of screening strategies, and it is not known,
which is the most optimal approach. The results of a national study of ELST surveillance
among Danish vHL patients indicated that specific patterns of audiologic parameters in
patients with ELSTs, indicating that a distinct audiologic pattern may be typical in ELST
development, perhaps even before the ELST is detectable on MRI. However, a larger study of
audiologic parameters in vHL patients with and without diagnosed ELSTs is needed in order to
fully investigate such a model and its use in early ELST detection.
Objective The overall objective of this study is to establish audiologic characteristics
among vHL patients with and without ELST, and investigate whether specific patterns in
audiometric parameters correspond to different stages in ELST development.
Material and Methods:
The study is a multi-center prospective cohort study that includes adult vHL patients, who
are followed with clinical interviews about subjective audio-vestibular symptoms, MRI of the
inner ear, and audiometry.
Results of all subjects' audiological and radiologic examinations will be collected at the
Department of Cellular and Molecular Medicine, University of Copenhagen. Results will be
blinded with regard to ELST history and radiologic results and evaluated by a single senior
ear-nose-and-throat specialist, who will look for specific patterns in audiologic parameters
over time. Radiologic images will be blinded with regard to symptoms and audiological
examination results and will be evaluated by a single radiology specialist, who will look
only at the inner ear and surrounding structures for presence of imaging-visible ELSTs and
evaluate size and pattern of growth of ELSTs if possible. Audiometric characteristics will
be correlated with presence of MRI visible ELSTs and patients' subjectively reported
audio-vestibular symptoms to determine whether specific patterns of audiological parameters
are distinct for ELSTs and their stages of tumor growth.
A followed-up of all study participants is planned after 2, 5 and 10 years after patients'
last assessed audiological examinations included in the initial study.
The initiators of the project are responsible for evaluation and analysis of data, and are
required to inform local project managers of any differences in their evaluation of
examinations compared to the local evaluations of the same examinations.
Local project managers are required to inform all of their local participants the results of
their examinations. If any ELSTs are found in participants, local project managers must
offer management of the ELSTs according to local recommendations. The initiators of the
project will offer help and counseling in relation to ELST management and treatment if
necessary.
Considerations of biomedical research ethics:
The Danish part of the study has been approved by the Danish Regional Committees on
Biomedical Research, who have also approved that results from all participating institutions
outside of Denmark can be collected and analyzed in Denmark. Each participating institution
outside of Denmark must make sure that the study is also approved according to regional law.
Oral and written consent must be obtained from all subjects, and results must be coded
before data is sent to Denmark for analysis.
Data management:
The investigators have approval for the study from the Danish Data Protection Agency. All
data analysis will take place under the University of Copenhagen in Denmark.
Significance and perspectives:
The present study will clarify the significance of audiologic examination in ELST
surveillance and improve ELST screening for vHL patients.
Publication:
The results will be published in international, scientific journals. Collaborators will be
included ad co-authors in any publications of the results of this study according to
Vancouver rules.
Funding:
The project is financially supported as a subproject of a larger PhD project. Salary of the
PhD student, Marie Louise Mølgaard Binderup is financed by the Danish Cancer Society with
approximately181,000 Euros, while the expenses of operation of the PhD project is supported
by the Lundbeck Foundation with approximately 65,000 Euros, of which approximately 4,000
Euros is estimated to be used for expenses of the present subproject. The supporting
organisations solely provide financial support and have no influence on study design, the
execution of study, or publication of results. Initiators of this project will not apply for
further financial support for this subproject.
Collaborating institutions and participating patients will not receive any financial support
from the mentioned sources.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Recruiting |
NCT05810246 -
68Ga-NY104 PET/CT in Von Hippel-Lindau Disease
|
Phase 2 | |
Completed |
NCT01168440 -
Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease
|
Phase 2 | |
Recruiting |
NCT06194669 -
Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells
|
||
Recruiting |
NCT04074135 -
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
Enrolling by invitation |
NCT03979833 -
Drivers of Hypoxia-induced Angiogenesis in Tumor Development
|
||
Active, not recruiting |
NCT04458935 -
Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma
|
||
Recruiting |
NCT05737602 -
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
|
N/A | |
Recruiting |
NCT03749980 -
MyVHL: Patient Natural History Study
|
||
Recruiting |
NCT05424016 -
Propranolol and Von Hippel-Lindau Disease
|
N/A | |
Completed |
NCT00052013 -
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
|
Phase 2 | |
Recruiting |
NCT04924075 -
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
|
Phase 2 | |
Recruiting |
NCT03050268 -
Familial Investigations of Childhood Cancer Predisposition
|
||
Completed |
NCT02108002 -
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
|
Phase 1 | |
Not yet recruiting |
NCT05843305 -
A Study of BPI-452080 in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT03108066 -
PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT00062166 -
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
|